HURA patented RADuction® technology will optimize patient safety and decrease radiation exposure for over 100 million CT Scans in the U.S. each year. Decreasing radiation exposure, particularly using dynamic perfusion imaging, is critically important for 1.2M heart attack and ~800K stroke scans each year.
Our mission is to introduce a new CT method that will decrease radiation emissions, optimizing the functional capabilities of CT scanners. Decreasing radiation exposure will also drive significant increases in overall CT scanning, particularly in Cardiac, GI, Mobile, Pediatric, and Whole-Body imaging applications.
RADuction® does not degrade image quality at 75% dose reduction.
Pulsed and/or low dose X-ray radiation at pre-specified rotation angles, combined with innovative, patent-pending image reconstruction methods which preserve image quality and speed without compromising workflow.
RADuction® technology enables 75% or greater CT radiation dose reduction with no change to image quality or clinical workflow.
The Standard Method degrades images (causing ‘streaking artifacts’) compromise diagnostic validity. RADuction® does not degrade image quality at 75% or 87.5% dose reduction.
RADuction® is complimentary to existing OEM dose reduction techniques: It can be used in addition to existing OEM Methods to further decrease radiation exposure.
Decrease radiation exposure by 75% or greater and likelihood of radiation-related cancer & conditions.
Allow for more high dose CT exams (e.g. CT perfusion and angiography) for better diagnosis
Mitigation of radiation exposure disease costs. Improved healthcare service provision and quality.
Increased regulatory compliance. Improve function and competitiveness of CT scanners to drive sales.
HURA maintains exclusive IP and freedom to operate and license RADuctionTM Technology. Additional IP submissions planned for Q3 2019.
Phantom Validation Complete: Successful validation in American College of Radiology (ACR) phantom experiments, compliant with US FDA standards.
HURA has secured Letters of Support from OEMs supporting the development of RADuction® Technology.
FDA approval does not require Pre-Market clinical validation.Estimated 3-6 month FDA Clearance.
RADuction® Technology is also vetted by the prestigious U.S. National Institutes of Health Coulter Foundation Technology Commercialization Program.
Decrease radiation exposure and likelihood of radiation-related cancer & conditions.
Mr. Korczykowski served as a Senior Advisor at Brookline Capital Markets in NY and Senior Director, Clinical Operations at a publicly traded Biotech Company. He has 15 years of experience advancing clinical diagnostics and drug discovery & development efforts.
Wang is a world leading expert in medical imaging with over 20 years of experience. Dr. Wang also maintains longstanding R&D collaborations with large OEMs including Philips, Siemens, Samsung and Neusoft.
Director at Center for Functional NeuroImaging. Professor of Neurology & Radiology at University of Pennsylvania
Chief Commercial Advisor
& National Institute of Health Advisor
Associate Professor of Radiologic Science at University of Pennsylvania
Member of Science Advisory Board
Professor of Radiology; Director of Physics & Biology in Medicine Graduate Program; UCLA David Geffen School of Medicine
Medical Physicist
Ph.D. Candidate in Biomedical Engineering at University of Southern California
